|
Synonyms: ABT-555 | AE12-1Y-QL
Compound class:
Antibody
Comment: Elezanumab (ABT-555) is a fully human monoclonal antibody targeting repulsive guidance molecule-a (RGMA), in development as a potential therapy for multiple sclerosis (MS).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2013112922 [2]. |
| No information available. |
Summary of Clinical Use  |
| Elezanumab (ABT-555) is being evaluated in Phase 1 clinical trial in patients with relapsing forms of MS (see NCT02601885). |
| Mechanism Of Action and Pharmacodynamic Effects |
| Inhibition of RGMA is expected to promote regeneration and neuroprotection in MS [1], acting to concurrently block autoimmune demyelination and axon injury. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02601885 | A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis | Phase 1 Interventional | AbbVie | ||
